Pegnitzjoen

Pegnitzjoen is a medication used to treat multiple sclerosis. It is an immunosuppressive agent, which means that it works by suppressing or inhibiting the activity of the immune system.

The medication belongs to a class of drugs known as sphingosine 1-phosphate (S1P) receptor modulators. It works by binding to the S1P receptors in the body, which are involved in the activation of immune cells called lymphocytes.

Studies have shown that pegnitzjoen can help to reduce the number of relapses in patients with multiple sclerosis, as well as slow down the progression of disability. The medication was approved for use in the European Union in 2011, and has also been approved in other countries.

Pegnitzjoen is typically administered orally, in the form of a pill or capsule. It is usually taken once a day. The most common side effects of the medication include tingling or numbness in the hands or feet, as well as respiratory infections.

Serious side effects of pegnitzjoen can include an increased risk of infections, as well as blood disorders. Patients taking the medication are encouraged to be in contact with their healthcare provider regularly to discuss any side effects they may be experiencing.

Pegnitzjoen is contraindicated in patients with certain medical conditions, including liver disease and history of cancer. It is also not recommended for patients who are pregnant or breastfeeding.